Six of 20 patients with advanced melanoma treated with gene-modified T cells using a HLA-A*0201-restricted melan-A protein and melanoma antigen recognized by T cells 1 (MART-1)-specific TCR achieved partial remission (PR), those were suffered from dermatitis and uveitis (grade2) [27]. This evidence concerns the gene MLANA and skin disorder.